NCT07195916View on ClinicalTrials.gov

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 18, 2028

Study Completion Date

August 18, 2028

Conditions
Solid TumorsHematologic Malignancies
Interventions
DRUG

INCA036873

Intravenously (IV)

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY